Annual CFI
-$3.14 B
-$2.82 B-878.42%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual cash flow from investing activities is currently -$3.14 billion, with the most recent change of -$2.82 billion (-878.42%) on 31 December 2023. During the last 3 years, it has fallen by -$3.24 billion (-3260.66%). VRTX annual CFI is now -875.41% below its all-time high of $405.17 million, reached on 31 December 2007.VRTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$348.00 M
+$115.70 M+24.95%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly cash flow from investing activities is currently -$348.00 million, with the most recent change of +$115.70 million (+24.95%) on 30 September 2024. Over the past year, it has dropped by -$230.30 million (-195.67%). VRTX quarterly CFI is now -185.72% below its all-time high of $405.95 million, reached on 31 March 2011.VRTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$3.83 B
-$230.30 M-6.39%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM cash flow from investing activities is currently -$3.83 billion, with the most recent change of -$230.30 million (-6.39%) on 30 September 2024. Over the past year, it has dropped by -$1.75 billion (-84.39%). VRTX TTM CFI is now -859.30% below its all-time high of $505.01 million, reached on 30 June 2015.VRTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -878.4% | -195.7% | -84.4% |
| 3 y3 years | -3260.7% | -557.8% | -10000.0% |
| 5 y5 years | -1454.1% | -39.8% | -911.1% |
VRTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3260.7% | at low | -298.2% | +83.7% | <-9999.0% | at low |
| 5 y | 5 years | -3260.7% | at low | -242.8% | +83.7% | -3957.8% | at low |
| alltime | all time | -875.4% | at low | -185.7% | +83.7% | -859.3% | at low |
Vertex Pharmaceuticals Incorporated Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$348.00 M(-25.0%) | -$3.83 B(+6.4%) |
| June 2024 | - | -$463.70 M(-78.3%) | -$3.60 B(+4.6%) |
| Mar 2024 | - | -$2.14 B(+141.0%) | -$3.44 B(+9.6%) |
| Dec 2023 | -$3.14 B(+878.4%) | -$886.50 M(+653.2%) | -$3.14 B(+51.1%) |
| Sept 2023 | - | -$117.70 M(-61.3%) | -$2.08 B(-11.4%) |
| June 2023 | - | -$303.90 M(-83.4%) | -$2.35 B(+11.5%) |
| Mar 2023 | - | -$1.83 B(-1144.2%) | -$2.10 B(+555.2%) |
| Dec 2022 | -$321.10 M(-5.8%) | $175.60 M(-145.7%) | -$321.10 M(-49.1%) |
| Sept 2022 | - | -$384.20 M(+524.7%) | -$630.70 M(+110.7%) |
| June 2022 | - | -$61.50 M(+20.6%) | -$299.40 M(-5.7%) |
| Mar 2022 | - | -$51.00 M(-61.9%) | -$317.60 M(-6.8%) |
| Dec 2021 | -$340.90 M(-443.0%) | -$134.00 M(+153.3%) | -$340.90 M(-1024.9%) |
| Sept 2021 | - | -$52.90 M(-33.6%) | $36.86 M(-123.3%) |
| June 2021 | - | -$79.70 M(+7.3%) | -$158.18 M(+2309.0%) |
| Mar 2021 | - | -$74.30 M(-130.5%) | -$6.57 M(-106.6%) |
| Dec 2020 | $99.40 M(-108.0%) | $243.76 M(-198.3%) | $99.40 M(-109.5%) |
| Sept 2020 | - | -$247.94 M(-444.8%) | -$1.04 B(-0.1%) |
| June 2020 | - | $71.91 M(+127.1%) | -$1.04 B(-10.5%) |
| Mar 2020 | - | $31.67 M(-103.5%) | -$1.16 B(-5.7%) |
| Dec 2019 | -$1.24 B(+511.1%) | -$896.97 M(+260.2%) | -$1.24 B(+225.7%) |
| Sept 2019 | - | -$249.00 M(+396.1%) | -$379.23 M(+110.5%) |
| June 2019 | - | -$50.19 M(+28.2%) | -$180.12 M(-26.8%) |
| Mar 2019 | - | -$39.14 M(-4.3%) | -$246.23 M(+21.8%) |
| Dec 2018 | -$202.16 M(-58.2%) | -$40.90 M(-18.0%) | -$202.16 M(+11.1%) |
| Sept 2018 | - | -$49.89 M(-57.1%) | -$182.04 M(-49.1%) |
| June 2018 | - | -$116.30 M(-2457.6%) | -$357.43 M(+12.6%) |
| Mar 2018 | - | $4.93 M(-123.7%) | -$317.42 M(-34.3%) |
| Dec 2017 | -$483.33 M(-1043.3%) | -$20.79 M(-90.8%) | -$483.33 M(+69.2%) |
| Sept 2017 | - | -$225.28 M(+195.3%) | -$285.61 M(+1018.5%) |
| June 2017 | - | -$76.28 M(-52.6%) | -$25.53 M(+263.1%) |
| Mar 2017 | - | -$160.98 M(-191.0%) | -$7.03 M(-113.7%) |
| Dec 2016 | $51.24 M(-80.9%) | $176.94 M(+408.6%) | $51.24 M(-120.6%) |
| Sept 2016 | - | $34.79 M(-160.2%) | -$248.39 M(-35.3%) |
| June 2016 | - | -$57.78 M(-43.7%) | -$384.12 M(+702.1%) |
| Mar 2016 | - | -$102.71 M(-16.3%) | -$47.89 M(-117.8%) |
| Dec 2015 | $268.86 M(+227.8%) | -$122.69 M(+21.6%) | $268.86 M(-28.0%) |
| Sept 2015 | - | -$100.94 M(-136.2%) | $373.54 M(-26.0%) |
| June 2015 | - | $278.44 M(+30.1%) | $505.01 M(+59.6%) |
| Mar 2015 | - | $214.04 M(-1288.4%) | $316.45 M(+285.9%) |
| Dec 2014 | $82.01 M(-172.9%) | -$18.01 M(-159.0%) | $82.01 M(-514.4%) |
| Sept 2014 | - | $30.55 M(-66.0%) | -$19.79 M(+2376.8%) |
| June 2014 | - | $89.88 M(-540.4%) | -$799.00 K(-99.2%) |
| Mar 2014 | - | -$20.41 M(-83.0%) | -$95.37 M(-15.3%) |
| Dec 2013 | -$112.56 M(-73.6%) | -$119.81 M(-341.9%) | -$112.56 M(-881.4%) |
| Sept 2013 | - | $49.54 M(-1156.0%) | $14.40 M(-108.7%) |
| June 2013 | - | -$4.69 M(-87.5%) | -$166.36 M(-28.2%) |
| Mar 2013 | - | -$37.60 M(-625.4%) | -$231.71 M(-45.6%) |
| Dec 2012 | -$425.82 M(-300.5%) | $7.16 M(-105.5%) | -$425.82 M(-48.1%) |
| Sept 2012 | - | -$131.23 M(+87.4%) | -$820.75 M(+22.9%) |
| June 2012 | - | -$70.04 M(-69.8%) | -$668.08 M(+57.1%) |
| Mar 2012 | - | -$231.70 M(-40.2%) | -$425.24 M(-300.2%) |
| Dec 2011 | $212.41 M(+2809.4%) | -$387.78 M(-1908.2%) | $212.41 M(-50.7%) |
| Sept 2011 | - | $21.45 M(-87.6%) | $430.49 M(+5.9%) |
| June 2011 | - | $172.79 M(-57.4%) | $406.63 M(+48.1%) |
| Mar 2011 | - | $405.95 M(-339.2%) | $274.49 M(+3659.6%) |
| Dec 2010 | $7.30 M(-101.4%) | -$169.69 M(+6929.6%) | $7.30 M(-102.0%) |
| Sept 2010 | - | -$2.41 M(-105.9%) | -$370.78 M(+13.8%) |
| June 2010 | - | $40.65 M(-70.7%) | -$325.84 M(-27.6%) |
| Mar 2010 | - | $138.76 M(-125.3%) | -$450.15 M(-11.5%) |
| Dec 2009 | -$508.73 M(+41.1%) | -$547.78 M(-1388.1%) | -$508.73 M(+1516.6%) |
| Sept 2009 | - | $42.52 M(-150.8%) | -$31.47 M(-82.3%) |
| June 2009 | - | -$83.66 M(-204.3%) | -$177.85 M(+37.8%) |
| Mar 2009 | - | $80.18 M(-213.7%) | -$129.07 M(-64.2%) |
| Dec 2008 | -$360.65 M | -$70.52 M(-32.1%) | -$360.65 M(+146.3%) |
| Sept 2008 | - | -$103.86 M(+197.8%) | -$146.40 M(-205.5%) |
| June 2008 | - | -$34.87 M(-77.0%) | $138.72 M(+188.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$151.40 M(-205.3%) | $48.10 M(-88.1%) |
| Dec 2007 | $405.17 M(-294.4%) | $143.74 M(-20.7%) | $405.17 M(-2247.1%) |
| Sept 2007 | - | $181.26 M(-244.4%) | -$18.87 M(-89.5%) |
| June 2007 | - | -$125.50 M(-161.0%) | -$179.42 M(+297.9%) |
| Mar 2007 | - | $205.66 M(-173.4%) | -$45.09 M(-78.4%) |
| Dec 2006 | -$208.47 M(>+9900.0%) | -$280.30 M(-1453.3%) | -$208.47 M(-624.2%) |
| Sept 2006 | - | $20.71 M(+134.6%) | $39.77 M(-235.6%) |
| June 2006 | - | $8.83 M(-79.1%) | -$29.33 M(-861.6%) |
| Mar 2006 | - | $42.29 M(-231.9%) | $3.85 M(-322.3%) |
| Dec 2005 | -$1.73 M(-101.6%) | -$32.06 M(-33.7%) | -$1.73 M(-102.5%) |
| Sept 2005 | - | -$48.38 M(-215.2%) | $68.22 M(-49.4%) |
| June 2005 | - | $42.01 M(+14.5%) | $134.75 M(-2.0%) |
| Mar 2005 | - | $36.70 M(-3.1%) | $137.50 M(+28.0%) |
| Dec 2004 | $107.43 M(-10.2%) | $37.89 M(+108.9%) | $107.43 M(+5.5%) |
| Sept 2004 | - | $18.14 M(-59.5%) | $101.82 M(+51.2%) |
| June 2004 | - | $44.76 M(+574.3%) | $67.32 M(+367.9%) |
| Mar 2004 | - | $6.64 M(-79.4%) | $14.39 M(-88.0%) |
| Dec 2003 | $119.58 M(-849.2%) | $32.28 M(-297.3%) | $119.58 M(+21.4%) |
| Sept 2003 | - | -$16.36 M(+100.1%) | $98.50 M(-10.8%) |
| June 2003 | - | -$8.18 M(-107.3%) | $110.48 M(+38.1%) |
| Mar 2003 | - | $111.84 M(+898.4%) | $80.00 M(-601.2%) |
| Dec 2002 | -$15.96 M(-89.0%) | $11.20 M(-355.7%) | -$15.96 M(-73.1%) |
| Sept 2002 | - | -$4.38 M(-88.7%) | -$59.39 M(+277.3%) |
| June 2002 | - | -$38.66 M(-343.5%) | -$15.74 M(-49.4%) |
| Mar 2002 | - | $15.87 M(-149.3%) | -$31.12 M(-78.6%) |
| Dec 2001 | -$145.09 M(-52.8%) | -$32.23 M(-182.1%) | -$145.09 M(-56.1%) |
| Sept 2001 | - | $39.27 M(-172.7%) | -$330.35 M(-20.7%) |
| June 2001 | - | -$54.03 M(-44.9%) | -$416.39 M(+3.2%) |
| Mar 2001 | - | -$98.10 M(-54.9%) | -$403.40 M(+31.2%) |
| Dec 2000 | -$307.46 M(-944.7%) | -$217.49 M(+364.9%) | -$307.46 M(+239.1%) |
| Sept 2000 | - | -$46.78 M(+14.0%) | -$90.67 M(+343.7%) |
| June 2000 | - | -$41.03 M(+1799.6%) | -$20.43 M(-184.0%) |
| Mar 2000 | - | -$2.16 M(+208.6%) | $24.34 M(-33.1%) |
| Dec 1999 | $36.40 M(-278.4%) | -$700.00 K(-103.0%) | $36.40 M(+63.2%) |
| Sept 1999 | - | $23.46 M(+526.7%) | $22.30 M(+128.9%) |
| June 1999 | - | $3.74 M(-62.2%) | $9.74 M(-216.0%) |
| Mar 1999 | - | $9.90 M(-166.9%) | -$8.40 M(-58.8%) |
| Dec 1998 | -$20.40 M(-82.8%) | -$14.80 M(-235.8%) | -$20.40 M(-81.4%) |
| Sept 1998 | - | $10.90 M(-175.7%) | -$109.50 M(-15.8%) |
| June 1998 | - | -$14.40 M(+585.7%) | -$130.00 M(+450.8%) |
| Mar 1998 | - | -$2.10 M(-98.0%) | -$23.60 M(-80.1%) |
| Dec 1997 | -$118.80 M(+194.1%) | -$103.90 M(+982.3%) | -$118.80 M(+525.3%) |
| Sept 1997 | - | -$9.60 M(-110.4%) | -$19.00 M(-62.5%) |
| June 1997 | - | $92.00 M(-194.6%) | -$50.60 M(-63.2%) |
| Mar 1997 | - | -$97.30 M(+2273.2%) | -$137.40 M(+240.1%) |
| Dec 1996 | -$40.40 M(+39.3%) | -$4.10 M(-90.0%) | -$40.40 M(-16.5%) |
| Sept 1996 | - | -$41.20 M(-892.3%) | -$48.40 M(+545.3%) |
| June 1996 | - | $5.20 M(-1833.3%) | -$7.50 M(-44.9%) |
| Mar 1996 | - | -$300.00 K(-97.5%) | -$13.60 M(-53.1%) |
| Dec 1995 | -$29.00 M(+105.7%) | -$12.10 M(+3933.3%) | -$29.00 M(+835.5%) |
| Sept 1995 | - | -$300.00 K(-66.7%) | -$3.10 M(-111.4%) |
| June 1995 | - | -$900.00 K(-94.3%) | $27.20 M(-2042.9%) |
| Mar 1995 | - | -$15.70 M(-213.8%) | -$1.40 M(-90.1%) |
| Dec 1994 | -$14.10 M(-310.4%) | $13.80 M(-54.0%) | -$14.10 M(-42.0%) |
| Sept 1994 | - | $30.00 M(-201.7%) | -$24.30 M(-46.5%) |
| June 1994 | - | -$29.50 M(+3.9%) | -$45.40 M(+66.9%) |
| Mar 1994 | - | -$28.40 M(-888.9%) | -$27.20 M(-506.0%) |
| Dec 1993 | $6.70 M(-171.3%) | $3.60 M(-59.6%) | $6.70 M(-211.7%) |
| Sept 1993 | - | $8.90 M(-178.8%) | -$6.00 M(-13.0%) |
| June 1993 | - | -$11.30 M(-305.5%) | -$6.90 M(+155.6%) |
| Mar 1993 | - | $5.50 M(-160.4%) | -$2.70 M(-71.3%) |
| Dec 1992 | -$9.40 M(-62.7%) | -$9.10 M(-213.8%) | -$9.40 M(+3033.3%) |
| Sept 1992 | - | $8.00 M(-212.7%) | -$300.00 K(-96.4%) |
| June 1992 | - | -$7.10 M(+491.7%) | -$8.30 M(+591.7%) |
| Mar 1992 | - | -$1.20 M | -$1.20 M |
| Dec 1991 | -$25.20 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash flow from investing activities?
- What is the all time high annual CFI for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual CFI year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly CFI year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM cash flow from investing activities?
- What is the all time high TTM CFI for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM CFI year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash flow from investing activities?
The current annual CFI of VRTX is -$3.14 B
What is the all time high annual CFI for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash flow from investing activities is $405.17 M
What is Vertex Pharmaceuticals Incorporated annual CFI year-on-year change?
Over the past year, VRTX annual cash flow from investing activities has changed by -$2.82 B (-878.42%)
What is Vertex Pharmaceuticals Incorporated quarterly cash flow from investing activities?
The current quarterly CFI of VRTX is -$348.00 M
What is the all time high quarterly CFI for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash flow from investing activities is $405.95 M
What is Vertex Pharmaceuticals Incorporated quarterly CFI year-on-year change?
Over the past year, VRTX quarterly cash flow from investing activities has changed by -$230.30 M (-195.67%)
What is Vertex Pharmaceuticals Incorporated TTM cash flow from investing activities?
The current TTM CFI of VRTX is -$3.83 B
What is the all time high TTM CFI for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM cash flow from investing activities is $505.01 M
What is Vertex Pharmaceuticals Incorporated TTM CFI year-on-year change?
Over the past year, VRTX TTM cash flow from investing activities has changed by -$1.75 B (-84.39%)